Skip to main content

Table 1 Mean percentage of patients achieving PASI 75 response with psoriasis biologic treatments

From: Budget impact analysis of ustekinumab in the management of moderate to severe psoriasis in Greece

Agent Mean (%) 95% CI
Adalimumab 58 49–68
Etanercept 52 45–59
Infliximab 80 70–87
Ustekinumab 69 62–75
  1. aThe relevant dosing scheme for each product is presented in Table 3.
  2. CI, confidence interval; PASI, Psoriasis Area and Severity Index.
  3. Source: Reich et al., 2012.